In the HER2-low population, treatment with trastuzumab deruxtecan reduced the risk of disease progression or death by 38% compared with chemotherapy. The Food and Drug Administration (FDA ...

Enhertu (fam-trastuzumab deruxtecan-nxki) can cause side effects that range from mild to serious. More common side effects include hair loss, nausea, and vomiting. If Enhertu side effects become ...

This app uses Apple Intelligence to generate custom images on your device. You can choose from a list of suggested prompts, or you can enter your own description of an image and your iPhone will ...

Whether you’re looking to find a friend’s profile, checking to see if anyone is infringing on your copyrighted images, or hunting down the source of a viral meme, Facebook reverse image ...

The FDA approved datopotamab deruxtecan-dlnk for treatment of certain patients with advanced breast cancer. The agent improved PFS but not OS vs. investigator’s choice of chemotherapy.

The drug, known as datopotamab deruxtecan but marketed under the brand name Datroway, is intended to treat hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2 ...

Tokyo: D aichi Sankyo has announced that DATROWAY (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) ...

On January 17, 2025, the Food and Drug Administration (FDA) approved datopotamab deruxtecan-dlnk a Trop-2-directed antibody and topoisomerase inhibitor conjugate. This approval marks a significant ...

(RTTNews) - British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) announced Monday that their Datroway (datopotamab deruxtecan) has been approved in the United States for ...

The drug, known in development as datopotamab deruxtecan, or Dato-DXd, will be marketed under the brand name Datroway. Datroway is part of a class of therapies called antibody drug conjugates ...

The patients were randomly assigned to receive adjuvant treatment with T-DM1 at 3.6 mg/kg (n=743) or trastuzumab at 6 mg/kg (n=743) every 3 weeks for 14 cycles. Baseline characteristics were ...